We have been representing patients and their family in drug injury lawsuits for the past 15 years and is our main practice area.
Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.
Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.
Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.
We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.
If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.
We encourage you to submit a Drug Injury Law Case Review — it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.
While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.
It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.
Legal & Medical News: Featured Article
New FDA Rule Requires Drug Company To Replace Current Simple Pregnancy Category Designation With A Summary Of The Risks Of Using Zofran During Pregnancy
SUMMARY: Starting earlier this year drug injury products liability lawsuits alleging birth defects caused by the use of Zofran (ondansetron) during pregnancy for so-called “morning sickness” have been filed against the pharmaceutical company GlaxoSmithKline (also known as GSK or Glaxo).
In December 2014 the FDA issued a new regulatory rule that seems to require GlaxoSmithKline in the next couple of months to make an important decision which may impact the Zofran lawsuits, those already filed and those that will be filed in the future.
In particular, it seems that Glaxo will need to decide what, if anything, it will disclose, i.e., admits to know, as regards the association between Zofran and birth defects such as congenital heart defects and cleft palate or lip.
It will be interesting to check those Zofran drug label documents in a couple of months from now to see what revisions have been made by Glaxo to conform to this new FDA rule.
And it would not be a surprise if just how those Zofran label changes were made had something to do with the current Zofran – birth defects lawsuits.
- Attention Deficit Hyperactivity Disorder Drugs Concerta And Ritalin Get New Warnings For Rhabdomyolysis In US And Priapism In Canada
- Diabetes Drugs Kombiglyze And Onglyza: Heart Failure Side Effect Seems To Be Valid, And FDA Notes There Is A Possible Increased Risk Of All-Cause Mortality
- A 2004 Medical Journal Article Indicated A Possible Link Between The “Morning Sickness” Drug Use Of Zofran And Hypospadias
- In Canada, ADHD Drugs Like Adderall, Concerta, And Ritalin Are Getting New Warnings About Suicide-Related Adverse Events
- Diabetes Drugs Bydureon And Victoza: Thyroid Cancer Label Change In March 2015 Comes Without Much Notice
- YAZ / Yasmin Litigation Update For March 2015: According To Bayer’s 2014 Annual Report, “Additional lawsuits are anticipated.”
- Cardiovascular Safety Issues For Onglyza And Kombiglyze Will Be Discussed At April 2015 FDA Advisory Committee Meeting
- First 2015 Update On Fosamax Femur Fracture Litigation: Not Much New Information To Report Out
- A New Case Of Progressive Multifocal Leukoencephalopathy (PML) In A Patient Using Gilenya Is Reported By Novartis In Canada
- Various Drug Safety Issues Continue To Be Associated With Novartis Multiple Sclerosis (MS) Medication Gilenya
- Zofran Associated With Birth Defects When Used During Pregnancy As An “Off-Label” Morning Sickness Treatment
- Viagra / Cialis / Levitra: Prostate Cancer Recurrence When Used After Radical Prostatectomy Surgery